Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Biotest AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis B, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HBIG for cure | P2 |
Recruiting |
Hepatitis B, Chronic |
2025-05-30 |
|
| HBIG | P2 |
Recruiting |
Hepatitis B, Chronic|Hepatitis A |
2025-05-01 |
12% |